Market Place
Sourcing Support
eClinical elluminate Platform Supports argenx Data Oversight
24 Mar 2026 //
BUSINESSWIRE
Argenx Sets Annual Shareholders Meeting For May 6, 2026
20 Mar 2026 //
GLOBENEWSWIRE
Argenx To Present At TD Cowen Healthcare Conference
23 Feb 2026 //
GLOBENEWSWIRE
Argenx to Report FY 2025 Results and Q4 Update on February 26
19 Feb 2026 //
GLOBENEWSWIRE
Argenx To Present At J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
Argenx Telegraphs CEO Switch As Chief Drug Vyvgart Rolls Ahead
05 Jan 2026 //
FIERCE PHARMA
Argenx Updates Uplight Studies in Thyroid Eye Disease
15 Dec 2025 //
GLOBENEWSWIRE
Argenx Announces Results of Extraordinary General Meeting
18 Nov 2025 //
GLOBENEWSWIRE
Argenx Unveils Q3 2025 Financials and Business Update
30 Oct 2025 //
GLOBENEWSWIRE
Argenx To Report Q3 2025 Financial Results On October 30
23 Oct 2025 //
GLOBENEWSWIRE
Argenx To Hold Extraordinary Shareholders Meeting On Nov 18, 2025
03 Oct 2025 //
GLOBENEWSWIRE
Argenx to Present at Investor Conferences
28 Aug 2025 //
GLOBENEWSWIRE
Argenx`s R&D Webinar on ARGX-119 Set for September 16, 2025
19 Aug 2025 //
GLOBENEWSWIRE
Argenx`s Half Year 2025 Financial Results and Q2 Business Update
31 Jul 2025 //
GLOBENEWSWIRE
Argenx`s Half Year 2025 Financial Results and Q2 Update
24 Jul 2025 //
GLOBENEWSWIRE
Argenx Advances ARGX-119 for Congenital Myasthenic Syndromes
03 Jul 2025 //
INDPHARMAPOST
FDA flags ‘severe worsening’ of disease for argenx`s Vyvgart SC
02 Jul 2025 //
FIERCE PHARMA
Argenx announces Annual General Meeting Results
28 May 2025 //
GLOBENEWSWIRE
argenx Reports Q1 2025 Financial Results and Business Update
08 May 2025 //
GLOBENEWSWIRE
Argenx to Present at BofA Securities 2025 Health Care Conference
06 May 2025 //
GLOBENEWSWIRE
Argenx to Report Q1 2025 Results and Business Update on May 8
30 Apr 2025 //
GLOBENEWSWIRE
Argenx schedules Annual General Meeting for May 27, 2025
11 Apr 2025 //
GLOBENEWSWIRE
US FDA approves syringe version of Argenx`s immune disorder drug
11 Apr 2025 //
REUTERS
Argenx Shares VYVGART Data at AAN 2025 for gMG, CIDP
08 Apr 2025 //
GLOBENEWSWIRE
Argenx Showcases FcRn Data, Outcomes At AAN 2025 Meeting
07 Mar 2025 //
GLOBENEWSWIRE
Argenx Reports Full-Year 2024 Results & Q4 Business Update
27 Feb 2025 //
GLOBENEWSWIRE
argenx to Present at TD Cowen 45th Annual Healthcare Conference
25 Feb 2025 //
GLOBENEWSWIRE
Argenx To Report FY24 Financial Results & Q4 Update On Feb 27
20 Feb 2025 //
GLOBENEWSWIRE
Argenx Highlights 2025 Strategic Priorities
13 Jan 2025 //
GLOBENEWSWIRE
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 Jan 2025 //
GLOBENEWSWIRE
Halozyme Announces VYDURA Approval in Japan for CIDP
30 Dec 2024 //
PR NEWSWIRE
Steritas with Argenx for Steroid-Toxicity Clinical Outcome
19 Nov 2024 //
CONTRACTPHARMA
argenx to Participate at Upcoming Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Argenx sees early launch success for Vyvgart in CIDP
02 Nov 2024 //
FIERCE PHARMA
Argenx sees early launch success for Vyvgart in CIDP
01 Nov 2024 //
FIERCE PHARMA
argenx Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
argenx Q3 2024 Financial Results on October 31, 2024
24 Oct 2024 //
GLOBENEWSWIRE
Argenx adds 4 new targets to Halozyme collab for $30M
04 Oct 2024 //
FIERCE PHARMA
Argenx Publishes Adhere Study Data In The Lancet Neurology
19 Sep 2024 //
GLOBENEWSWIRE
argenx to Present at Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Argenx Reports H1 2024 Financials And Q2 Business Update
24 Jul 2024 //
GLOBENEWSWIRE
Argenx `s Biologic Vyvgart (Efgartigimod) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
Argenx To Report H1 2024 Results And Q2 Update On July 25
18 Jul 2024 //
GLOBENEWSWIRE
Zai Lab And Argenx Get China Approval For Efgartigimod In Myasthenia Gravis
16 Jul 2024 //
BUSINESSWIRE
J&J unwraps data on $6.5B autoimmune asset as it crash argenx and UCB`s party
01 Jul 2024 //
FIERCE BIOTECH
Argenx Highlights Autoimmune Pipeline with New Multifocal Motor Neuropathy Data
25 Jun 2024 //
GLOBENEWSWIRE
Argenx snares 2nd US nod for Vyvgart Hytrulo
22 Jun 2024 //
FIERCE PHARMA
argenx To Unveil `Vision 2030` During Upcoming R&D Day On July 16, 2024
17 Jun 2024 //
GLOBENEWSWIRE
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
GLOBENEWSWIRE
argenx to Present at BofA Securities 2024 Health Care Conference
07 May 2024 //
GLOBENEWSWIRE
argenx announces results of Annual General Meeting of Shareholders
06 May 2024 //
GLOBENEWSWIRE
argenx To Report Q1 2024 Results, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Argenx gears up to launch Vyvgart in next potential indication
17 Apr 2024 //
FIERCE PHARMA
argenx: VYVGART Drives Transformative Autoimmune Outcomes
15 Apr 2024 //
GLOBENEWSWIRE
argenx Announces Approval of VYVGART in Japan for immune Thrombocytopenia
26 Mar 2024 //
GLOBENEWSWIRE
Argenx starts unbranded push ahead of hoped-for label expansion
29 Feb 2024 //
FIERCE PHARMA
Argenx rolls out campaign for rare autoimmune condition as it awaits FDA ruling
28 Feb 2024 //
ENDPTS
argenx to Present at Upcoming Investor Conferences
26 Feb 2024 //
GLOBENEWSWIRE
